Journal of Medicinal Chemistry
ARTICLE
’ ASSOCIATED CONTENT
(9) Gilbert-Sirieix, M.; Ripoche, H.; Malvy, C.; Massaad-Massade, L.
Effects of silencing RET/PTC1 junction oncogene in human papillary
thyroid carcinoma cells. Thyroid 2010, 20, 1053–1065.
(10) Brummelkamp, T. R.; Bernards, R.; Agami, R. A system for
stable expression of short interfering RNAs in mammalian cells. Science
2002, 296, 550–553.
(11) Bertling, W. M.; Gareis, M.; Paspaleeva, V.; Zimmer, A.;
Kreuter, J.; Nurnberg, E.; Harrer, P. Use of liposomes, viral capsids,
and nanoparticles as DNA carriers. Biotechnol. Appl. Biochem. 1991,
13, 390–405.
S
Supporting Information. Reverse phase HPLC chroma-
b
togram of the purified RET/PTC1 siRNA-SQ and spectroscopic
data for compounds 4 and 5. This material is available free of
’ AUTHOR INFORMATION
Corresponding Author
(12) Halder, J.; Kamat, A. A.; Landen, C. N., Jr.; Han, L. Y.;
Lutgendorf, S. K.; Lin, Y. G.; Merritt, W. M.; Jennings, N. B.; Chavez-
Reyes, A.; Coleman, R. L.; Gershenson, D. M.; Schmandt, R.; Cole,
S. W.; Lopez-Berestein, G.; Sood, A. K. Focal adhesion kinase targeting
using in vivo short interfering RNA delivery in neutral liposomes for
ovarian carcinoma therapy. Clin. Cancer Res. 2006, 12, 4916–4924.
(13) Zimmermann, T. S.; Lee, A. C.; Akinc, A.; Bramlage, B.;
Bumcrot, D.; Fedoruk, M. N.; Harborth, J.; Heyes, J. A.; Jeffs, L. B.;
John, M.; Judge, A. D.; Lam, K.; McClintock, K.; Nechev, L. V.; Palmer,
L. R.; Racie, T.; Rohl, I.; Seiffert, S.; Shanmugam, S.; Sood, V.;
Soutschek, J.; Toudjarska, I.; Wheat, A. J.; Yaworski, E.; Zedalis, W.;
Koteliansky, V.; Manoharan, M.; Vornlocher, H. P.; MacLachlan, I.
RNAi-mediated gene silencing in non-human primates. Nature 2006,
441, 111–114.
*For L.M.-M.: phone, 33 1 42 11 62 42; fax, 33 1 42 11 53 14;
e-mail, liliane.massade@igr.fr. For P.C.: phone, 33 1 46 83 53 96;
fax, 33 1 46 61 93 34; e-mail, patrick.couvreur@u-psud.fr.
’ ACKNOWLEDGMENT
The research leading to these results has received funding
from the European Research Council under the European
Community’s Seventh Framework Programme FP7/2007-2013
Grant Agreement No. 249835.
’ ABBREVIATIONS USED
(14) Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien,
R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.;
John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.;
Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.;
Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H. P.
Therapeutic silencing of an endogenous gene by systemic administration
of modified siRNAs. Nature 2004, 432, 173–178.
(15) Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of cationic
lipids and cationic polymers in gene delivery. J. Controlled Release 2006,
114, 100–119.
(16) Kuo, W. T.; Huang, H. Y.; Huang, Y. Y. Intracellular trafficking,
metabolism and toxicity of current gene carriers. Curr. Drug Metab.
2009, 10, 885–894.
(17) Thompson, M. P.; Chien, M. P.; Ku, T. H.; Rush, A. M.;
Gianneschi, N. C. Smart lipids for programmable nanomaterials. Nano
Lett. 2010, 10, 2690–2693.
siRNA, small interfering RNA; PTC, papillary thyroid carcinoma;
RET, rearranged during transfection; ON, oligonucleotide; RISC,
RNA-induced silencing complex; TK, tyrosine kinase; RPL13A, ribo-
somal protein 13A; siRNA CT, siRNA control; qRT-PCR, real time
quantitative reverse transcription PCR; Ct, cycle threshold; FCS,
fetal calf serum; DMEM, Dulbecco’s modified Eagle medium; SQ,
squalene; NP, nanoparticle; TEAA, triethylammonium acetate; ddC,
dideoxycytosine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; SDS, sodium dodecyl sulfate; THF, tetrahydro-
furan; PBS, phosphate buffered saline; DMF, dimethylformamide;
DABCO, 1,4-diazabicyclo[2.2.2]octane; DEPC, diethyl pyrocarbo-
nate; RP-HPLC, reverse phase high-performance liquid chromatog-
raphy; MALDI-TOF MS, matrix-assisted laser desorption ionizat-
ion time-of-flight mass spectrometer; TEM, transmission electron
microscopy
(18) Wu, Y.; Sefah, K.; Liu, H.; Wang, R.; Tan, W. DNA aptamer-
micelle as an efficient detection/delivery vehicle toward cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 5–10.
’ REFERENCES
(19) Wolfrum, C.; Shi, S.; Jayaprakash, K. N.; Jayaraman, M.; Wang,
G.; Pandey, R. K.; Rajeev, K. G.; Nakayama, T.; Charrise, K.; Ndungo,
E. M.; Zimmermann, T.; Koteliansky, V.; Manoharan, M.; Stoffel, M.
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.
Nat. Biotechnol. 2007, 25, 1149–1157.
(20) Godeau, G.; Staedel, C.; Barthelemy, P. Lipid-conjugated
oligonucleotides via “click chemistry” efficiently inhibit hepatitis C virus
translation. J. Med. Chem. 2008, 51, 4374–4376.
(1) Gimm, O. Thyroid cancer. Cancer Lett. 2001, 163, 143–156.
(2) Hundahl, S. A.; Cady, B.; Cunningham, M. P.; Mazzaferri, E.;
McKee, R. F.; Rosai, J.; Shah, J. P.; Fremgen, A. M.; Stewart, A. K.;
Holzer, S. Initial results from a prospective cohort study of 5583 cases of
thyroid carcinoma treated in the United States during 1996. U.S. and
German Thyroid Cancer Study Group. An American College of
Surgeons Commission on Cancer Patient Care Evaluation study. Cancer
2000, 89, 202–217.
(21) Gissot, A.; Camplo, M.; Grinstaff, M. W.; Barthelemy, P.
Nucleoside, nucleotide and oligonucleotide based amphiphiles: a suc-
cessful marriage of nucleic acids with lipids. Org. Biomol. Chem. 2008,
6, 1324–1333.
(22) Miettinen, T. A.; Vanhanen, H. Serum concentration and
metabolism of cholesterol during rapeseed oil and squalene feeding.
Am. J. Clin. Nutr. 1994, 59, 356–363.
(23) Reddy, L. H.; Couvreur, P. Squalene: a natural triterpene for use
in disease management and therapy. Adv. Drug Delivery Rev. 2009,
61, 1412–1426.
(24) Reddy, L. H.; Dubernet, C.; Mouelhi, S. L.; Marque, P. E.;
Desmaele, D.; Couvreur, P. A new nanomedicine of gemcitabine
displays enhanced anticancer activity in sensitive and resistant leukemia
types. J. Controlled Release 2007, 124, 20–27.
(3) Smanik, P. A.; Furminger, T. L.; Mazzaferri, E. L.; Jhiang, S. M.
Breakpoint characterization of the ret/PTC oncogene in human papil-
lary thyroid carcinoma. Hum. Mol. Genet. 1995, 4, 2313–2318.
(4) Santoro, M.; Melillo, R. M.; Fusco, A. RET/PTC activation in
papillary thyroid carcinoma: European Journal of Endocrinology Prize
Lecture. Eur. J. Endocrinol. 2006, 155, 645–653.
(5) Santoro, M.; Melillo, R. M.; Carlomagno, F.; Fusco, A.; Vecchio,
G. Molecular mechanisms of RET activation in human cancer. Ann. N.Y.
Acad. Sci. 2002, 963, 116–121.
(6) DeLellis, R. A. Pathology and genetics of thyroid carcinoma.
J. Surg. Oncol. 2006, 94, 662–669.
(7) Jhiang, S. M. The RET proto-oncogene in human cancers.
Oncogene 2000, 19, 5590–5597.
(8) Mizuno, T.; Iwamoto, K. S.; Kyoizumi, S.; Nagamura, H.;
Shinohara, T.; Koyama, K.; Seyama, T.; Hamatani, K. Preferential
induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene
2000, 19, 438–443.
(25) Bildstein, L.; Dubernet, C.; Marsaud, V.; Chacun, H.;
Nicolas, V.; Gueutin, C.; Sarasin, A.; Benech, H.; Lepetre-Mouelhi, S.;
Desmaele, D.; Couvreur, P. Transmembrane diffusion of gemcitabine
4075
dx.doi.org/10.1021/jm2000272 |J. Med. Chem. 2011, 54, 4067–4076